Literature DB >> 23801337

Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy.

Akira Ema1, Keishi Yamashita, Shinich Sakuramoto, Guoqin Wang, Hiroaki Mieno, Masayuki Nemoto, Tomotaka Shibata, Natsuya Katada, Shiro Kikuchi, Masahiko Watanabe.   

Abstract

BACKGROUND: S-1 is an oral anticancer drug widely used in postoperative adjuvant therapy for patients in Japan with stage II/III gastric cancer. Candidates for more intense adjuvant treatments need to be identified, particularly among patients with stage III cancer.
METHODS: Univariate and multivariate analyses were conducted for patients with stage II/III gastric cancer who underwent surgery and received S-1 postoperatively between 2000 and 2010.
RESULTS: Factors indicating poor prognosis identified by univariate analysis include male sex (P = 0.022), age ≥67 years (P = 0.021), intestinal-type histology (P = 0.049), lymph node ratio ≥16.7 % (P < 0.0001), open surgery (P = 0.039), as well as the 13th JGCA stage (P < 0.0001) and the 14th JGCA/7th International Union Against Cancer (UICC) stage (P < 0.0001). Multivariate analysis revealed that lymph node ratio ≥16.7 % and intestinal-type histology were significant as predictors of prognosis, independent from the pathological stages. Based on these and other findings, stage IIIC cancer on the 14th JGCA/7th UICC stage system in combination with the lymph node ratio could identify patients with extremely high risk for recurrence
CONCLUSIONS: Our current findings suggest that lymph node ratio ≥16.7 % in combination with the new staging system could be a useful prognostic indicator in advanced gastric cancer. Because these high-risk patients cannot be identified preoperatively by any diagnostic tool, further improvement in postoperative adjuvant therapy is warranted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23801337     DOI: 10.1007/s10120-013-0253-y

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  23 in total

1.  The superiority of ratio-based lymph node staging in gastric carcinoma.

Authors:  Kentaro Inoue; Yasushi Nakane; Hitoshi Iiyama; Mutsuya Sato; Tatsuya Kanbara; Koji Nakai; Syunichiro Okumura; Keigo Yamamichi; Koshiro Hioki
Journal:  Ann Surg Oncol       Date:  2002 Jan-Feb       Impact factor: 5.344

2.  PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma.

Authors:  Diana L Mandelker; Keishi Yamashita; Yutaka Tokumaru; Koshi Mimori; David L Howard; Yoichi Tanaka; Andre Lopes Carvalho; Wei-Wen Jiang; Hannah Lui Park; Myoung Sook Kim; Motonobu Osada; Masaki Mori; David Sidransky
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

3.  Japanese Classification of Gastric Carcinoma - 2nd English Edition -

Authors: 
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

4.  A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002.

Authors:  Hiroshi Katayama; Seiji Ito; Takeshi Sano; Daisuke Takahari; Junki Mizusawa; Narikazu Boku; Akira Tsuburaya; Masanori Terashima; Mitsuru Sasako
Journal:  Jpn J Clin Oncol       Date:  2012-04-23       Impact factor: 3.019

5.  Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience.

Authors:  Donato Nitti; Alberto Marchet; Matteo Olivieri; Alessandro Ambrosi; Roberto Mencarelli; Claudio Belluco; Mario Lise
Journal:  Ann Surg Oncol       Date:  2003-11       Impact factor: 5.344

6.  Lymph node metastasis density (ND)-factor association with malignant degree and ND40 as "non-curative factor" in gastric cancer.

Authors:  Keishi Yamashita; Akira Ooki; Shinichi Sakuramoto; Shiroh Kikuchi; Natsuya Katada; Nobuyuki Kobayashi; Masahiko Watanabe
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

7.  New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma.

Authors:  Ugwuji N Maduekwe; Gregory Y Lauwers; Carlos Fernandez-Del-Castillo; David L Berger; Charles M Ferguson; David W Rattner; Sam S Yoon
Journal:  Ann Surg Oncol       Date:  2010-01-23       Impact factor: 5.344

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

10.  The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: results from an Italian multicentric study in 1853 patients.

Authors:  Alberto Marchet; Simone Mocellin; Alessandro Ambrosi; Paolo Morgagni; Domenico Garcea; Daniele Marrelli; Franco Roviello; Giovanni de Manzoni; Annamaria Minicozzi; Giovanni Natalini; Francesco De Santis; Luca Baiocchi; Arianna Coniglio; Donato Nitti
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

View more
  19 in total

1.  Effect of expressions of tumor necrosis factor α and interleukin 1B on peritoneal metastasis of gastric cancer.

Authors:  Lin Guo; Jin-Lei Ou; Tong Zhang; Liang Ma; Long-Fei Qu
Journal:  Tumour Biol       Date:  2015-06-12

2.  Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer.

Authors:  Kazuki Kano; Takanobu Yamada; Kouji Yamamoto; Keisuke Komori; Hayato Watanabe; Kentaro Hara; Yota Shimoda; Yukio Maezawa; Hirohito Fujikawa; Toru Aoyama; Hiroshi Tamagawa; Naoto Yamamoto; Haruhiko Cho; Manabu Shiozawa; Norio Yukawa; Takaki Yoshikawa; Soichiro Morinaga; Yasushi Rino; Munetaka Masuda; Takashi Ogata; Takashi Oshima
Journal:  Ann Surg Oncol       Date:  2020-05-18       Impact factor: 5.344

Review 3.  A Comprehensive Review on Pharmacotherapeutics of Three Phytochemicals, Curcumin, Quercetin, and Allicin, in the Treatment of Gastric Cancer.

Authors:  Atousa Haghi; Haniye Azimi; Roja Rahimi
Journal:  J Gastrointest Cancer       Date:  2017-12

4.  Robust vascular invasion concurrent with intense EGFR immunostaining can predict recurrence in patients with stage IB node-negative gastric cancer.

Authors:  Ippeita Araki; Marie Washio; Keishi Yamashita; Kei Hosoda; Akira Ema; Hiroaki Mieno; Hiromitsu Moriya; Natsuya Katada; Shiro Kikuchi; Masahiko Watanabe
Journal:  Surg Today       Date:  2017-12-18       Impact factor: 2.549

5.  Outcome predictors for patients with stage II/III gastric cancer who undergo gastrectomy and S-1 adjuvant chemotherapy.

Authors:  Yoshinori Fujiwara; Shuichi Fukuda; Masanori Tsujie; Kotaro Kitani; Keisuke Inoue; Tomonori Hayashi; Hajime Ishikawa; Masao Yukawa; Masatoshi Inoue
Journal:  Oncol Lett       Date:  2017-05-31       Impact factor: 2.967

6.  A long non-coding RNA signature to improve prognosis prediction of gastric cancer.

Authors:  Xiaoqiang Zhu; Xianglong Tian; Chenyang Yu; Chaoqin Shen; Tingting Yan; Jie Hong; Zheng Wang; Jing-Yuan Fang; Haoyan Chen
Journal:  Mol Cancer       Date:  2016-09-20       Impact factor: 27.401

7.  Clinical Influence of the Lymph Node Ratio on Lymph Node Metastasis-positive Gastric Cancer Patients Who Receive Curative Treatment.

Authors:  Toru Aoyama; Kesikeu Komori; Ayako Tamagawa; Masato Nakazano; Kentaro Hara; Itaru Hashimoto; Hiroshi Tamagawa; Kenki Segami; Yukio Maezawa; Kazuki Kano; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

8.  miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway.

Authors:  Weiguo Cao; Weiping Yang; Rong Fan; Hao Li; Jinsong Jiang; Mei Geng; Yening Jin; Yunlin Wu
Journal:  Tumour Biol       Date:  2013-09-26

9.  Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.

Authors:  Akira Ema; Mina Waraya; Keishi Yamashita; Kenichi Kokubo; Hirosuke Kobayashi; Keika Hoshi; Yoshiko Shinkai; Hiroshi Kawamata; Kazunori Nakamura; Hiroshi Nishimiya; Natsuya Katada; Masahiko Watanabe
Journal:  Cancer Med       Date:  2014-08-26       Impact factor: 4.452

10.  Exclusive Association of p53 Mutation with Super-High Methylation of Tumor Suppressor Genes in the p53 Pathway in a Unique Gastric Cancer Phenotype.

Authors:  Mina Waraya; Keishi Yamashita; Akira Ema; Natsuya Katada; Shiro Kikuchi; Masahiko Watanabe
Journal:  PLoS One       Date:  2015-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.